[VIEW] agent=Care Transitions Program Manager | scenario_id=111 | rounds=20

--- Round 0 ---
[R0.1] Privacy & Data Governance Officer (speak, public): To ensure we're making an informed decision about scaling the post-discharge Remote Patient Monitoring program, I'd like to understand the day-to-day operations and expected outcomes. Can you walk me through how the monitoring work is currently handled?
[R0.2] Care Transitions Program Manager (speak, public): Currently, our care team handles the monitoring work by managing an average of 12 alerts per day, with an escalation service-level agreement (SLA) of 2 hours. We've seen positive results in our pilot, with 30-day readmissions decreasing from 21% to 15% among the 180 patients enrolled across 2 hospitals. The condition mix includes both heart failure and COPD patients.
[R0.3] Payer Contracting & Finance Director (speak, public): That's great to hear about the positive results from the pilot. To better understand the financial implications of scaling this program, can you share more details on how the care team is currently staffed and if there are any anticipated changes in staffing needs as we expand?

--- Round 1 ---
[R1.1] Privacy & Data Governance Officer (speak, public): Thank you for the operational insights. I'd like to understand the broader financial and reimbursement landscape. Can you share more about the current reimbursement structure for RPM services and any anticipated changes that could impact our decision to scale?
[R1.2] Care Transitions Program Manager (speak, public): Our current staffing model is based on a caseload of 55 active patients per RN, with weekend coverage handled by 1 RN per day. As for the financial implications, I'd like to hear from the Payer Contracting & Finance Director regarding the reimbursement structure and any anticipated changes.
[R1.3] Payer Contracting & Finance Director (speak, public): The current reimbursement structure for RPM services is based on an average reimbursement of $120 per member-month, with 2 billable months per enrollee. We've also modeled avoided readmissions at 38 per quarter, with a variable cost of $6,200 per readmission. Additionally, we're at risk for a Hospital Readmissions Reduction Program (HRRP) penalty of $1.4 million, given our current readmission index of 1.08. As we scale the program, we'll need to consider these financial implications carefully.

--- Round 2 ---
[R2.1] Privacy & Data Governance Officer (speak, public): To better assess our readiness for scaling the RPM program, I'd like to clarify a few points. Care Transitions Program Manager, can you confirm if the current staffing model is sustainable as we scale, and are there any potential bottlenecks or resourcing constraints we should be aware of? Additionally, Payer Contracting & Finance Director, could you elaborate on any non-public payer commitments or signals that might impact our reporting or data flows as we expand the program?
[R2.2] Care Transitions Program Manager (speak, public): To address the concerns about scaling the RPM program, I can confirm that our current staffing model is based on a caseload of 55 active patients per RN. However, I must highlight that our device logistics have been a challenge, with a kit turnaround time of 2.5 days and a loss rate of 3%. Regarding potential bottlenecks, I'd like to emphasize that our main concern is maintaining the current level of care as we scale. I'd like to hear from the Privacy & Data Governance Officer regarding any potential governance escalations that could impact our rollout timing.
[R2.3] Payer Contracting & Finance Director (speak, public): To address the concerns about scaling the RPM program, I'd like to provide some additional financial context. Our year-1 total program cost is estimated to be $920,000, with staffing being a significant cost driver at $540,000 per year, assuming 6 RN FTEs. Devices and shipping also contribute substantially to the cost, at $260,000 per year for 350 kits. Given these costs, it's essential to consider the potential return on investment as we scale the program. I'd like to hear from the Care Transitions Program Manager regarding the operational feasibility of maintaining or improving our current level of care as we expand.

--- Round 3 ---
[R3.1] Privacy & Data Governance Officer (speak, public): To summarize, we've gathered valuable insights into the operational feasibility, financial implications, and potential governance considerations for scaling the RPM program. From a governance standpoint, I'd like to highlight that our current PHI transmission controls, patient consent requirements, and data minimization practices are in place. However, we still have 3 open sections in our DPA that need to be addressed. I'd like to propose that we continue scaling the program while working to resolve the outstanding DPA sections and assessing potential non-public payer commitments that may impact our reporting or data flows.
[R3.2] Care Transitions Program Manager (speak, public): To summarize, we've gathered valuable insights into the operational feasibility, financial implications, and potential governance considerations for scaling the RPM program. I agree that we should continue scaling the program while working to resolve the outstanding DPA sections and assessing potential non-public payer commitments that may impact our reporting or data flows. Based on our current staffing model and device logistics, I'm confident that we can maintain our current level of care as we expand. However, I'll need to work closely with the team to ensure that we're addressing any potential bottlenecks and resourcing constraints. I recommend that we move forward with scaling the program, with a focus on maintaining our current level of care and addressing any governance or financial concerns that arise.
[R3.3] Payer Contracting & Finance Director (speak, public): To summarize, we've gathered valuable insights into the operational feasibility, financial implications, and potential governance considerations for scaling the RPM program. Based on the information shared, I believe that scaling the program is economically justified, given the potential return on investment and the avoided readmissions. However, I do recommend that we continue to monitor our staffing intensity and clinical impact as we expand. I'd like to propose that we move forward with scaling the program, with a focus on maintaining our current level of care and addressing any governance or financial concerns that arise.

--- Round 4 ---
[R4.1] Privacy & Data Governance Officer (speak, public): I appreciate the thorough discussion and the insights shared by all. Based on the information gathered, it seems that scaling the RPM program is feasible from both operational and financial standpoints, with some governance considerations that we need to address. To summarize, we will move forward with scaling the program while continuing to work on resolving the outstanding DPA sections and assessing any non-public payer commitments. I'll draft a final recommendation document that incorporates our discussion points and highlights the key governance considerations. I'll share it with both of you for review before finalizing.
[R4.2] Care Transitions Program Manager (speak, public): I agree with the summary and the proposed next steps. I'm confident that we've gathered sufficient information to move forward with scaling the RPM program. I'll continue to work closely with the team to ensure that we're addressing any operational concerns and maintaining our current level of care as we expand.
[R4.3] Payer Contracting & Finance Director (speak, public): I agree with the summary and the proposed next steps. I'm confident that we've gathered sufficient information to move forward with scaling the RPM program. I'll continue to work closely with the finance team to ensure that we're addressing any financial concerns and optimizing our reimbursement strategy as we expand.

--- Round 5 ---
[R5.1] Privacy & Data Governance Officer (leave, public): 
[R5.2] Care Transitions Program Manager (leave, public): 
[R5.3] Payer Contracting & Finance Director (leave, public): 

--- Round 6 ---
[R6.1] Privacy & Data Governance Officer (leave, public): 
[R6.2] Care Transitions Program Manager (leave, public): 
[R6.3] Payer Contracting & Finance Director (leave, public): 

--- Round 7 ---
[R7.1] Privacy & Data Governance Officer (leave, public): 
[R7.2] Care Transitions Program Manager (leave, public): 
[R7.3] Payer Contracting & Finance Director (leave, public): 

--- Round 8 ---
[R8.1] Privacy & Data Governance Officer (leave, public): 
[R8.2] Care Transitions Program Manager (leave, public): 
[R8.3] Payer Contracting & Finance Director (leave, public): 

--- Round 9 ---
[R9.1] Privacy & Data Governance Officer (leave, public): 
[R9.2] Care Transitions Program Manager (leave, public): 
[R9.3] Payer Contracting & Finance Director (leave, public): 

--- Round 10 ---
[R10.1] Privacy & Data Governance Officer (leave, public): 
[R10.2] Care Transitions Program Manager (leave, public): 
[R10.3] Payer Contracting & Finance Director (leave, public): 

--- Round 11 ---
[R11.1] Privacy & Data Governance Officer (leave, public): 
[R11.2] Care Transitions Program Manager (leave, public): 
[R11.3] Payer Contracting & Finance Director (leave, public): 

--- Round 12 ---
[R12.1] Privacy & Data Governance Officer (leave, public): 
[R12.2] Care Transitions Program Manager (leave, public): 
[R12.3] Payer Contracting & Finance Director (leave, public): 

--- Round 13 ---
[R13.1] Privacy & Data Governance Officer (leave, public): 
[R13.2] Care Transitions Program Manager (leave, public): 
[R13.3] Payer Contracting & Finance Director (leave, public): 

--- Round 14 ---
[R14.1] Privacy & Data Governance Officer (leave, public): 
[R14.2] Care Transitions Program Manager (leave, public): 
[R14.3] Payer Contracting & Finance Director (leave, public): 

--- Round 15 ---
[R15.1] Privacy & Data Governance Officer (leave, public): 
[R15.2] Care Transitions Program Manager (leave, public): 
[R15.3] Payer Contracting & Finance Director (leave, public): 

--- Round 16 ---
[R16.1] Privacy & Data Governance Officer (leave, public): 
[R16.2] Care Transitions Program Manager (leave, public): 
[R16.3] Payer Contracting & Finance Director (leave, public): 

--- Round 17 ---
[R17.1] Privacy & Data Governance Officer (leave, public): 
[R17.2] Care Transitions Program Manager (leave, public): 
[R17.3] Payer Contracting & Finance Director (leave, public): 

--- Round 18 ---
[R18.1] Privacy & Data Governance Officer (leave, public): 
[R18.2] Care Transitions Program Manager (leave, public): 
[R18.3] Payer Contracting & Finance Director (leave, public): 

--- Round 19 ---
[R19.1] Privacy & Data Governance Officer (leave, public): 
[R19.2] Care Transitions Program Manager (leave, public): 
[R19.3] Payer Contracting & Finance Director (leave, public): 

